Sanofi Consumer Healthcare India Limited (SANOFICONR) Fair Value & Analysis
Healthcare · IN · Market cap ₹107B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price −1.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹3,939 – ₹5,292 · fair‑value band ₹1,460 – ₹4,219 · the ₹4,625 price screens above the ₹1,896 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sanofi Consumer Healthcare India Limited (SANOFICONR) currently trades at ₹4,625, while our model-based Fair Value estimate is ₹1,896 — implying the stock looks roughly 59.0% overvalued today. We read business quality at 71/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Sanofi Consumer Healthcare India Limited generated revenue of ₹9.3B at a net margin of 27.6%. Revenue grew 32.8% year over year. It earns a return on equity of 73.1%. The balance sheet holds a net cash position of ₹3.5B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.
Revenue & earnings trend
FY2023 – FY2025 · reported fiscal years
Sanofi Consumer Healthcare India Limited reported revenue of ₹8.8B in FY2025 versus ₹5.4B in FY2023, a compound +27.0%/yr. Reported net income was ₹2.4B in FY2025, compounding +20.7%/yr from FY2023.
Is SANOFICONR fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 316.37 MXN | -96% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sanofi Consumer Healthcare India Limited (SANOFICONR) undervalued?
What is the fair value of SANOFICONR?
What is the quality score of SANOFICONR?
What is the revenue of Sanofi Consumer Healthcare India Limited (SANOFICONR)?
What is the net profit margin of SANOFICONR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.